SGLT2 inhibitors and sleep apnea outcomes in overweight adults
Official title: Adipose Dysfunction, Imaging, Physiology, and Outcomes with SGLT2i's for Sleep Apnea: The ADIPOSA Study
Funded at Case Western Reserve University · NIH-11402545 · Data updated 2026-11-12
This study tests whether an SGLT2 inhibitor can improve sleep apnea-related health issues in overweight adults with moderate to severe sleep apnea.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Case Western Reserve University NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | July 20, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2026 |
| Award (this year) | $622,800 |
| NIH project number | 5R01HL163627-04 |
| Project ID | NIH-11402545 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults aged 21 and older with overweight or obesity (BMI 25-40 kg/m2) and moderate to severe obstructive sleep apnea, with or without type 2 diabetes.
✕Less likely to help
Individuals without obesity-related sleep apnea or who are not candidates for SGLT2 inhibitors may not benefit from this study.
What this research studies
The ADIPOSA study is a two-center clinical trial in overweight or obese adults with moderate to severe obstructive sleep apnea, comparing ertugliflozin 15 mg daily to placebo for six months. It will look at how the drug changes body fat distribution, airway anatomy, and physiologic traits related to sleep apnea, as well as clinical symptoms. The study also explores blood biomarkers of adiposity and fluid balance to understand mechanisms that might link metabolism to sleep apnea. Participants will undergo imaging, physiology testing, and clinical assessments to track changes over time. Results could reveal a new metabolic approach to reducing sleep apnea burden in people with obesity and/or type 2 diabetes.
Why it matters
Potential benefit: If successful, participants could experience improvements in sleep apnea symptoms and related health measures through a metabolic treatment approach.
How similar studies have gone: Previous work suggests metabolic interventions can influence sleep apnea traits, but this specific SGLT2 inhibitor approach is novel in this context and exploratory outcomes are being tested.
Where this research is happening
-
Case Western Reserve University
Cleveland, United States Active
Researchers
- Principal investigator: Neeland, Ian Jason — Case Western Reserve University
- Study coordinator: Neeland, Ian Jason
Related research
Other NIH-funded projects on the same topics.
-
Improving WTC responder mental health with personalized sleep treatment for COMISA
Aimed at helping World Trade Center responders who have both insomnia and sleep apnea feel better by using a tailored combination of sleep therapies.
-
Central sleep apnea: how combined therapies could help you breathe better
This NIH grant explores how a combination of therapies, including a breathing device and a drug, might reduce central sleep apnea for people with heart failure or opioid use, by targeting the body’s breathing control system.
-
Mechanisms of sex-specific responses to sleep apnea therapies
A research project at NYU School of Medicine is exploring how men and women may respond differently to treatments for obstructive sleep apnea and related heart risk.
-
Deep learning to predict obstruction site and guide sleep apnea treatment
A patient-focused project uses snoring sounds and AI to predict where your airway collapses during sleep and to guide personalized treatments.
-
Personalized DISE-guided surgery for sleep apnea in children with Down syndrome
A personalized surgical approach guided by DISE sleep-endoscopy is being tested to better treat sleep apnea in children with Down syndrome who don’t always improve after standard surgery.
-
Biomarkers to understand obstructive sleep apnea using microRNAs
A study at the University of Pennsylvania will look for microRNA signs in the blood that reflect how bad sleep apnea is and how well CPAP therapy works for patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.